Efficacy Versus Gel

Enstilar® is more effective than Dovobet® (calcipotriol/ betamethasone dipropionate) gel at achieving treatment success*

Over the recommended treatment period (4 weeks for Enstilar® and 8 weeks for Dovobet gel [non-scalp]):1

King et al. 2016: Retrospective analysis of the Phase III PSO-ABLE study. PSO-ABLE was a Phase III, randomised, vehicle-controlled, investigator-blinded, multicentre study in patients aged ≥18 years with mild or moderate psoriasis vulgaris (trunk and/or limbs). Treatment success was defined as patients who achieved clear or almost clear skin with at least a two-step improvement in disease severity according to PGA. 36.2% (n=59 /163) of patients using Enstilar® achieved treatment success by week 4 vs 22.5% (n=38/169) using Dovobet gel by week 8 (the recommended treatment period for ‘non-scalp’ areas; p=0.003).1

CI: confidence interval; OR: odds ratio; PASI: psoriasis area severity index; PGA: physician’s global assessment.

UK Enstilar® foam and Dovobet® gel cost comparison:3

Pack sizeTreatmentBasic NHS Price
60 gEnstilar® foam£39.68
Dovobet® gel£37.21
2 x 60 g
(120 g)
Enstilar® foam£79.36
Dovobet® gel£69.11
Patient applying foam spray

Are you still using Dovobet® gel?

Optimise your patient’s treatment and advance them to Enstilar®

Return to the efficacy overview
See the difference in patients

LEO Pharma Product Licence Indications
Enstilar® is indicated for the topical treatment of psoriasis vulgaris in adults.1  Prescribing information can be found here
Dovobet® gel is indicated for the topical treatment of stable plaque psoriasis vulgaris amenable to topical therapy in adults. Prescribing information can be found here

  1. King C et al.Poster 237 presented at the 5th Psoriasis International Network Annual Meeting, Paris, France, 5–7 July 2016.
  2. Koo J et al. J Dermatolog Treat2016; 27(2):120–127.
  3. BNF formulary. https://www.medicinescomplete.com/mc/bnf/current/. Last accessed August 2019.
MAT-26550 July 2019

Keep in touch with LEO Pharma

Latest product information, consultation tools, hot topics in dermatology and congress updates.  Be the first to know with LEO Pharma. Sign up

MAT-29941 November 2019

Holler Box